Newlink Genetics reported 4.56M in Selling and Administration Expenses for its second fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Selling And Administration Expenses Change
Agenus AGEN:US $ 16.65M 298K
Bristol Myers Squibb BMY:US $ 1.88B 215M
Capricor Therapeutics CAPR:US 1.79M 115.61K
Celldex Therapeutics CLDX:US $ 4.31M 185K
Eli Lilly And LLY:US $ 1.69B 109.7M
Idera Pharmaceuticals IDRA:US $ 2.47M 684K
Intrexon XON:US $ 20M 1.3M
Merk MRK:US $ 2.25B 376M
Nektar Therapeutics NKTR:US $ 29.56M 2.12M
Newlink Genetics NLNK:US 4.56M 604K
Pfizer PFE:US $ 2.79B 134M
Prothena PRTA:US 11.03M 93K
Sarepta Therapeutics SRPT:US $ 72.35M 1.22M
Vascular Biogenics VBLT:US 1.48M 192K
YTE INCY:US $ 168.86M 15.06M